Literature DB >> 30920766

A Machine Learning Classifier for Assigning Individual Patients With Systemic Sclerosis to Intrinsic Molecular Subsets.

Jennifer M Franks1, Viktor Martyanov2, Guoshuai Cai3, Yue Wang2, Zhenghui Li2, Tammara A Wood2, Michael L Whitfield1.   

Abstract

OBJECTIVE: High-throughput gene expression profiling of tissue samples from patients with systemic sclerosis (SSc) has identified 4 "intrinsic" gene expression subsets: inflammatory, fibroproliferative, normal-like, and limited. Prior methods required agglomerative clustering of many samples. In order to classify individual patients in clinical trials or for diagnostic purposes, supervised methods that can assign single samples to molecular subsets are required. We undertook this study to introduce a novel machine learning classifier as a robust accurate intrinsic subset predictor.
METHODS: Three independent gene expression cohorts were curated and merged to create a data set covering 297 skin biopsy samples from 102 unique patients and controls, which was used to train a machine learning algorithm. We performed external validation using 3 independent SSc cohorts, including a gene expression data set generated by an independent laboratory on a different microarray platform. In total, 413 skin biopsy samples from 213 individuals were analyzed in the training and testing cohorts.
RESULTS: Repeated cross-fold validation identified consistent and discriminative markers using multinomial elastic net, performing with an average classification accuracy of 87.1% with high sensitivity and specificity. In external validation, the classifier achieved an average accuracy of 85.4%. Reanalyzing data from a previous study, we identified subsets of patients that represent the canonical inflammatory, fibroproliferative, and normal-like subsets.
CONCLUSION: We developed a highly accurate classifier for SSc molecular subsets for individual patient samples. The method can be used in SSc clinical trials to identify an intrinsic subset on individual samples. Our method provides a robust data-driven approach to aid clinical decision-making and interpretation of heterogeneous molecular information in SSc patients.
© 2019, American College of Rheumatology.

Entities:  

Mesh:

Year:  2019        PMID: 30920766      PMCID: PMC6764877          DOI: 10.1002/art.40898

Source DB:  PubMed          Journal:  Arthritis Rheumatol        ISSN: 2326-5191            Impact factor:   15.483


  25 in total

1.  Feature specific quantile normalization enables cross-platform classification of molecular subtypes using gene expression data.

Authors:  Jennifer M Franks; Guoshuai Cai; Michael L Whitfield
Journal:  Bioinformatics       Date:  2018-06-01       Impact factor: 6.937

Review 2.  Transforming growth factor β--at the centre of systemic sclerosis.

Authors:  Robert Lafyatis
Journal:  Nat Rev Rheumatol       Date:  2014-08-19       Impact factor: 20.543

3.  Regularization Paths for Generalized Linear Models via Coordinate Descent.

Authors:  Jerome Friedman; Trevor Hastie; Rob Tibshirani
Journal:  J Stat Softw       Date:  2010       Impact factor: 6.440

4.  COMP: a candidate molecule in the pathogenesis of systemic sclerosis with a potential as a disease marker.

Authors:  R Hesselstrand; A Kassner; D Heinegård; T Saxne
Journal:  Ann Rheum Dis       Date:  2007-12-07       Impact factor: 19.103

5.  Belimumab for the Treatment of Early Diffuse Systemic Sclerosis: Results of a Randomized, Double-Blind, Placebo-Controlled, Pilot Trial.

Authors:  Jessica K Gordon; Viktor Martyanov; Jennifer M Franks; Elana J Bernstein; Jackie Szymonifka; Cynthia Magro; Horatio F Wildman; Tammara A Wood; Michael L Whitfield; Robert F Spiera
Journal:  Arthritis Rheumatol       Date:  2017-12-29       Impact factor: 10.995

Review 6.  Molecular stratification and precision medicine in systemic sclerosis from genomic and proteomic data.

Authors:  Viktor Martyanov; Michael L Whitfield
Journal:  Curr Opin Rheumatol       Date:  2016-01       Impact factor: 5.006

7.  Intrinsic gene expression subsets of diffuse cutaneous systemic sclerosis are stable in serial skin biopsies.

Authors:  Sarah A Pendergrass; Raphael Lemaire; Ian P Francis; J Matthew Mahoney; Robert Lafyatis; Michael L Whitfield
Journal:  J Invest Dermatol       Date:  2012-02-09       Impact factor: 8.551

8.  A novel multi-network approach reveals tissue-specific cellular modulators of fibrosis in systemic sclerosis.

Authors:  Jaclyn N Taroni; Casey S Greene; Viktor Martyanov; Tammara A Wood; Romy B Christmann; Harrison W Farber; Robert A Lafyatis; Christopher P Denton; Monique E Hinchcliff; Patricia A Pioli; J Matthew Mahoney; Michael L Whitfield
Journal:  Genome Med       Date:  2017-03-23       Impact factor: 11.117

9.  Molecular characterization of systemic sclerosis esophageal pathology identifies inflammatory and proliferative signatures.

Authors:  Jaclyn N Taroni; Viktor Martyanov; Chiang-Ching Huang; J Matthew Mahoney; Ikuo Hirano; Brandon Shetuni; Guang-Yu Yang; Darren Brenner; Barbara Jung; Tammara A Wood; Swati Bhattacharyya; Orit Almagor; Jungwha Lee; Arlene Sirajuddin; John Varga; Rowland W Chang; Michael L Whitfield; Monique Hinchcliff
Journal:  Arthritis Res Ther       Date:  2015-07-29       Impact factor: 5.156

10.  g:Profiler-a web server for functional interpretation of gene lists (2016 update).

Authors:  Jüri Reimand; Tambet Arak; Priit Adler; Liis Kolberg; Sulev Reisberg; Hedi Peterson; Jaak Vilo
Journal:  Nucleic Acids Res       Date:  2016-04-20       Impact factor: 16.971

View more
  19 in total

1.  Recent advances steer the future of systemic sclerosis toward precision medicine.

Authors:  Gemma Lepri; Michael Hughes; Cosimo Bruni; Marco Matucci Cerinic; Silvia Bellando Randone
Journal:  Clin Rheumatol       Date:  2019-11-23       Impact factor: 2.980

Review 2.  Machine Learning in Rheumatic Diseases.

Authors:  Mengdi Jiang; Yueting Li; Chendan Jiang; Lidan Zhao; Xuan Zhang; Peter E Lipsky
Journal:  Clin Rev Allergy Immunol       Date:  2021-02       Impact factor: 8.667

3.  Abatacept in Early Diffuse Cutaneous Systemic Sclerosis: Results of a Phase II Investigator-Initiated, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial.

Authors:  Dinesh Khanna; Cathie Spino; Sindhu Johnson; Lorinda Chung; Michael L Whitfield; Christopher P Denton; Veronica Berrocal; Jennifer Franks; Bhavan Mehta; Jerry Molitor; Virginia D Steen; Robert Lafyatis; Robert W Simms; Anna Gill; Suzanne Kafaja; Tracy M Frech; Vivien Hsu; Robyn T Domsic; Janet E Pope; Jessica K Gordon; Maureen D Mayes; Elena Schiopu; Amber Young; Nora Sandorfi; Jane Park; Faye N Hant; Elana J Bernstein; Soumya Chatterjee; Flavia V Castelino; Ali Ajam; Yue Wang; Tammara Wood; Yannick Allanore; Marco Matucci-Cerinic; Oliver Distler; Ora Singer; Erica Bush; David A Fox; Daniel E Furst
Journal:  Arthritis Rheumatol       Date:  2019-12-10       Impact factor: 10.995

Review 4.  Biomarkers in systemic sclerosis.

Authors:  Brian Skaug; Shervin Assassi
Journal:  Curr Opin Rheumatol       Date:  2019-11       Impact factor: 5.006

Review 5.  Big data in systemic sclerosis: Great potential for the future.

Authors:  Mislav Radic; Tracy M Frech
Journal:  J Scleroderma Relat Disord       Date:  2020-07-06

6.  Clinical and Molecular Findings after Autologous Stem Cell Transplantation or Cyclophosphamide for Scleroderma: Handling Missing Longitudinal Data.

Authors:  Lynette Keyes-Elstein; Ashley Pinckney; Ellen Goldmuntz; Beverly Welch; Jennifer M Franks; Viktor Martyanov; Tammara A Wood; Leslie Crofford; Maureen Mayes; Peter McSweeney; Richard Nash; George Georges; M E Csuka; Robert Simms; Daniel Furst; Dinesh Khanna; E William St Clair; Michael L Whitfield; Keith M Sullivan
Journal:  Arthritis Care Res (Hoboken)       Date:  2021-09-17       Impact factor: 4.794

7.  Global skin gene expression analysis of early diffuse cutaneous systemic sclerosis shows a prominent innate and adaptive inflammatory profile.

Authors:  Brian Skaug; Dinesh Khanna; William R Swindell; Monique E Hinchcliff; Tracy M Frech; Virginia D Steen; Faye N Hant; Jessica K Gordon; Ami A Shah; Lisha Zhu; W Jim Zheng; Jeffrey L Browning; Alexander M S Barron; Minghua Wu; Sudha Visvanathan; Patrick Baum; Jennifer M Franks; Michael L Whitfield; Victoria K Shanmugam; Robyn T Domsic; Flavia V Castelino; Elana J Bernstein; Nancy Wareing; Marka A Lyons; Jun Ying; Julio Charles; Maureen D Mayes; Shervin Assassi
Journal:  Ann Rheum Dis       Date:  2019-11-25       Impact factor: 19.103

Review 8.  Emerging drugs for the treatment of scleroderma: a review of recent phase 2 and 3 trials.

Authors:  David Roofeh; Alain Lescoat; Dinesh Khanna
Journal:  Expert Opin Emerg Drugs       Date:  2020-10-26       Impact factor: 4.191

Review 9.  Shared and distinct mechanisms of fibrosis.

Authors:  Jörg H W Distler; Andrea-Hermina Györfi; Meera Ramanujam; Michael L Whitfield; Melanie Königshoff; Robert Lafyatis
Journal:  Nat Rev Rheumatol       Date:  2019-11-11       Impact factor: 20.543

10.  Machine learning integration of scleroderma histology and gene expression identifies fibroblast polarisation as a hallmark of clinical severity and improvement.

Authors:  Dana E Orange; Jessica K Gordon; Kimberly Showalter; Robert Spiera; Cynthia Magro; Phaedra Agius; Viktor Martyanov; Jennifer M Franks; Roshan Sharma; Heather Geiger; Tammara A Wood; Yaxia Zhang; Caryn R Hale; Jackie Finik; Michael L Whitfield
Journal:  Ann Rheum Dis       Date:  2020-10-07       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.